Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Authors:
  • PFPatrick M. Forde
    Patrick M. Forde
  • JCJamie E. Chaft
    Jamie E. Chaft
  • KSKellie N. Smith
    Kellie N. Smith
  • VAValsamo Anagnostou
    Valsamo Anagnostou
  • TCTricia R. Cottrell
    Tricia R. Cottrell
  • MZMarianna Zahurak
    Marianna Zahurak
  • SYStephen C. Yang
    Stephen C. Yang
  • DJDavid R. Jones
    David R. Jones
  • SBStephen Broderick
    Stephen Broderick
  • RBRichard J. Battafarano
    Richard J. Battafarano
  • MVMoises J. Velez
    Moises J. Velez

Abstract
Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non–small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated with delays in surgery. Of the 21 tumors that were removed, 20 were completely resected. A major pathological response occurred in 9 of 20 resected tumors (45%). Responses occurred in both PD-L1–positive and PD-L1–negative tumors. There was a significant correlation between the pathological response and the pretreatment tumor mutational burden. The number of T-cell clones that were found in both the tumor and peripheral blood increased systemically after PD-1 blockade in eight of nine patients who were evaluated. Mutation-associated, neoantigen-specific T-cell clones from a primary tumor with a complete response on pathological assessment rapidly expanded in peripheral blood at 2 to 4 weeks after treatment; some of these clones were not detected before the administration of nivolumab. Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute–Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621.)
Funding Information
  • International Association for the Study of Lung Cancer
  • LUNGevity Foundation
  • MacMillan Foundation
  • Lung Cancer Foundation of America
  • National Cancer Institute (CA006973, CA121113, CA180950, CA193145, P30 CA006973, P30 CA008748, R01 CA142779, T32 CA193145)
  • ECOG-ACRIN
  • Commonwealth Foundation
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • Bristol-Myers Squibb
  • Bloomberg–Kimmel Institute for Cancer Immunotherapy
  • Stand Up To Cancer (SU2C-AACR-DT1012)

This publication has 31 references indexed in Scilit: